Watch the interview with Ultimovacs CMO Jens Bjørheim below.
Ultimovacs has announced topline data from the Phase II NIPU trial evaluating the universal cancer vaccine UV1 in mesothelioma. An independent review of the results has concluded that the primary endpoint, progression-free survival, has not been met. At the same time, a local assessment has found a statistically significant improvement in progression-free survival for patients receiving UV1 treatment. BioStock spoke with Jens Bjørheim, CMO at Ultimovacs, to get a full overview of the results.